Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis

Clinical and Experimental Immunology

Volumn 185, Issue 2, 2016, Pages 263-270

  Verwoerd, A ^a   Hijdra, D ^a,b   Vorselaars, A D M ^a   Crommelin, H A ^a,c   van Moorsel, C H M ^a,d   Grutters, J C ^a,d   Claessen, A M E ^b  

^a Interstitial Lung Diseases Centre of Excellence   (Netherlands)

^b Department of Medical Microbiology and Immunology ^*  (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

infliximab; sarcoidosis; sTNFR2; Tregs; TNFR2

Indexed keywords

CD4 ANTIGEN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ALPHA; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SARCOIDOSIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

EID: 84978919919     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12808     Document Type: Article

References (24)

1. Valeyre D, Prasse A, Nunes H et al. Sarcoidosis. Lancet 2014; 383:1155–67.
2. Vorselaars AD, Crommelin HA, Deneer VH et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 2015; 46:175–85.
3. Zissel G. Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 2014; 35:307–15.
4. Grant CR, Liberal R, Mieli-Vergani G et al. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun Rev 2015; 14:105–16.
5. Rappl G, Pabst S, Riemann D et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol 2011; 140:71–83.
6. Miyara M, Amoura Z, Parizot C et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203:359–70.
7. Broos CE, van Nimwegen M, Kleinjan A et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir Res 2015; 16:108.
8. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277–85.
9. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007; 204:33–9.
10. Nie H, Zheng Y, Li R et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med 2013; 19:322–8.
11. Valencia X, Stephens G, Goldbach-Mansky R et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108:253–61.
12. Chen X, Baumel M, Mannel DN et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007; 179:154–61.
13. Chen X, Wu X, Zhou Q et al. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol 2013; 190:1076–84.
14. Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology (Oxf) 2015; 54:768–75.
15. Lainez B, Fernandez-Real JM, Romero X et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol 2004; 16:169–77.
16. Xanthoulea S, Pasparakis M, Kousteni S et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004; 200:367–76.
17. Heaney ML, Golde DW. Soluble receptors in human disease. J Leukoc Biol 1998; 64:135–46.
18. Canete JD, Albaladejo C, Hernandez MV et al. Clinical significance of high levels of soluble tumour necrosis factor-alpha receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study. Rheumatology (Oxf) 2011; 50:721–8.
19. Chen X, Hamano R, Subleski JJ et al. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol 2010; 185:174–82.
20. Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett 2011; 585:3611–8.
21. Wehrens EJ, Mijnheer G, Duurland CL et al. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-AKT hyperactivation in effector cells. Blood 2011; 118:3538–48.
22. Cheng J, Phong B, Wilson DC et al. Akt fine-tunes NF-kappaB-dependent gene expression during T cell activation. J Biol Chem 2011; 286:36076–85.
23. Van Zee KJ, Kohno T, Fischer E et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845–9.
24. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7:231–40.